Form 4: MapLight Therapeutics Director Acquires Shares, Options

Timothy John Garnett, a Director at MapLight Therapeutics, Inc., reported the acquisition of 3,932 restricted stock units and the grant of a stock option for 14,902 shares.

Summary

• Timothy John Garnett, a Director at MapLight Therapeutics, Inc., has reported transactions involving company securities.
• On June 23, 2026, Garnett acquired 3,932 restricted stock units (RSUs) under the Issuer's 2025 Equity Incentive Plan.
• These RSUs will vest on the earlier of June 23, 2027, or the date of the Issuer's next annual stockholder meeting, contingent on Garnett's continued service.
• The RSUs were granted as part of the company's non-employee director compensation policy.
• Following this acquisition, Garnett beneficially owns 53,457 shares of voting common stock.
• Additionally, Garnett was granted a stock option to purchase 14,902 shares of voting common stock at an exercise price of $28.64.
• This stock option also vests on the earlier of June 23, 2027, or the next annual stockholder meeting, subject to continued service.
• The shares underlying the RSUs and the stock option are held indirectly through the Timothy J Garnett Revocable Trust dated U/A 09/22/2021, where Garnett is the sole trustee with voting and dispositive power.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents routine insider transactions related to director compensation and does not inherently signal a change in the company's fundamental performance or outlook.

Positives

• Director Garnett's acquisition of RSUs and stock options indicates continued alignment with the company's long-term performance.
• The grant of equity awards under the company's incentive plan suggests a commitment to retaining and incentivizing key personnel.
• The vesting schedule tied to continued service and future annual meetings aligns executive incentives with shareholder value creation.

Risks

• The vesting of RSUs and stock options is contingent on the Reporting Person's Continuous Service, meaning departure from the company before vesting dates could result in forfeiture.
• The exercise price of the stock option ($28.64) implies a certain valuation expectation for the company's stock.

Future Outlook

The future outlook is tied to the vesting of the granted RSUs and stock options, which are contingent on the reporting person's continued service and the company's performance, as indicated by the vesting schedule tied to the next annual stockholder meeting.

Industry Context

StockSavvy.ai notes that the reporting of equity grants and acquisitions by directors is a standard practice for publicly traded companies, particularly in the biotechnology sector where retention of experienced leadership is crucial for navigating complex research and development pipelines and regulatory landscapes.

Stakeholder Impact

• Shareholders: The grants align director incentives with long-term shareholder value, but the actual impact depends on future stock performance.
• Employees: The existence of an equity incentive plan for directors may reflect a broader compensation philosophy that could extend to other employees.
• Management: The transactions reinforce the role of equity compensation in retaining key leadership.

Next Steps

• Monitoring the vesting of RSUs and stock options on June 23, 2027, or the next annual stockholder meeting.
• Observing the continued service of Timothy John Garnett as a Director.

Key Dates

Keywords

MapLight Therapeutics, MPLT, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Compensation, Equity Incentive Plan, Beneficial Ownership, Securities Exchange Act